Having established success in cancer, biopharma is now looking to leverage CAR T therapies against a new target, autoimmune ...

Treatment with inebilizumab was associated with continued improvement in patients with AChR+ generalized myasthenia gravis, according to 52-week results from the MINT trial.

Myasthenia gravis (MG) is a acquired autoimmune disease mediated by ... cGVHD is a late complication of allo-HSCT that may involve neuropathy presenting as myositis, immune-mediated neuropathy, ...

myositis and ANCA-associated vasculitis across three parallel cohorts Investigator-Sponsored Trial (IST) expands the development of NKX019 to neuromuscular autoimmune disease myasthenia gravis ...

The patients are part of Cabaletta’s RESET program across inflammatory muscle condition myositis ... generalized myasthenia gravis, multiple sclerosis and pemphigus vulgaris (PV) across 50 ...

Dermatomyositis: The safety and efficacy of Octagam 10% for the treatment of myositis was assessed in one prospective, double-blind, randomized, placebo-controlled, multicenter study in 95 adults ...